Last week's BBC programme The price of life highlighted the plight of cancer sufferers awaiting a decision by NICE, the National Institute for Health and Clinical Excellence, on a new drug that could add years to their lives. If approved by NICE, the drug, called revlimid and used to treat a cancer called multiple myeloma, could be prescribed freely on the NHS. If rejected, the prohibitive cost would spell the end of the line for many patients. In the light of the suffering facing myeloma patients and their families, the main criterion for NICE's decisions — cost-effectiveness — seems almost inhumane. But exactly what kind of mathematical considerations go into NICE's calculations?
posted by Plus @ 12:00 PM